The effect of tissue factor pathway inhibitor on hepatic ischemic reperfusion injury of the rat

Transplantation

Volumn 67, Issue 1, 1999, Pages 45-53

  Yoshimura, Norio ^a   Kobayashi, Yosifumi ^a   Nakamura, Kenji ^a   Yamagishi, Hisakazu ^a   Oka, Takahiro ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BLOOD CLOTTING; CELL DAMAGE; IMMUNOHISTOCHEMISTRY; KUPFFER CELL; LIVER ISCHEMIA; LIVER TRANSPLANTATION; MALE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY;

ANIMALS; BIOLOGICAL MARKERS; BLOOD; BLOOD COAGULATION; GRAFT SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; ISCHEMIA; LIPOPROTEINS; LIVER; LIVER CIRCULATION; MALE; RATS; RATS, INBRED LEW; RECOMBINANT PROTEINS; REPERFUSION INJURY; STAINING AND LABELING;

EID: 0033556648     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199901150-00007     Document Type: Article

References (46)

1. Colletti ML, Remick GD, Burtch DG, Kunkel LS, Strieter MR, Campbell ADJ. Role of tumor necrosis factor-α in the pathophysiologic alterations after hepatic ischemic/reperfusion injury in the rat. J Clin Invest 1990; 85: 1936.
2. Jaeschke H, Farhood A, Smith WC. Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB J 1990; 4: 3355.
3. Jaeschke H, Farhood A. Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am J Physiol 1991; 260 (23): G355.
4. Jaeschke H, Farhood A, Bautista PA, Spolarics Z, Spitzer JJ. Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. Am J Physiol 1993; 264F: G801.
5. Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1.
6. Levi M, ten Cate H, Bauer AK, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114.
7. Warr AT, Rao MVL, Rapaport IS. Disseminated intravascular coaglation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481.
8. Kobayashi Y, Yoshimura N, Nakamura K, et al. Expression of tissue factor in hepatic ischemic-reperfusion injury of the rat. Transplantation 1998; 66: 708.
9. Kamikubo Y, Nakahara Y, Takemoto S, et al. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett 1997; 407: 116.
10. Kamikubo Y, Hamuro T, Matsuda J, et al, Antithrombotic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravascular coagulation in rats: concerted effect with antithrombin. Thromb Haemostasis 1996; 76: 621.
11. Marmur JD, Rossikhina M, Giha A, et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. Clin Invest 1993; 91: 2253.
12. Jang Y, Guzman LA, Lincoff M, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041.
13. Elsayed YS, Nakagawa K, Kamikubo Y, et al. Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and in vivo distribution in a rat DIC model. Am J Clin Pathol 1996; 106: 574.
14. Edwards R, Rickles F, Bobrove A. Mononuclear cell tissue factor: cell of origin and requirements for activation. Blood 1979; 54: 359.
15. Maynard J, Dreyer B, Stemerman M. Tissue factor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts. Blood 1977; 50: 387.
16. Colucci M, Balconi G, Lorenzet R, et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893.
17. Bevilacqua PM, Pober SJ, Majeau RG, Cotran SR, Gimbrone AMJ. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160: 618.
18. Brand K, Fowler JB, Edgington ST, Mackman N. Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide. Mol Cell Biol 1991; 11: 4732.
19. Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989; 9: 2752.
20. Hashimoto Y, Hirohata S, Kashiwado T, Itoh K, Ishi H. Cytokine regulation of hemostatic property and IL-6 production of human endothelial cells. Inflammation 1992; 16: 613.
21. Moore LK, Andreoli PS, Esmon LN, Esmon TC, Bang UN. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79; 124.
22. Archipoff G, Beretz A, Freyssinet J-M, Klein-Soyer C, Brisson C, Cazenave J-P. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester. Biochem J 1991; 273: 679.
23. Nawroth PP, Stern MD. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740.
24. Drake AT, Cheng J, Chang A, Taylor FBJ. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 1993; 142: 1458.
25. Wilcox JN, Smith KM, Schwartz SM. Localization of tissue factor in the normal vessel wall and in the artherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839.
26. Lindahl AK. Tissue factor pathway inhibitor.: from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc Res 1997; 33: 286.
27. Bajaj MS, Kuppuswamy MN, Saito H, et al. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869.
28. Novotny WF, Girard TJ, Miletich JP, et al. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988; 72: 2020.
29. Novotny WF, Palmier M, Wun TC, et al. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991; 78: 394.
30. Wun TC, Kretzmer KK, Girard TJ, et al. Cloning and characterization of a cDNA coding for the lipoprotein-associated type inhibitory domains. J Biol Chem 1998; 263: 6001.
31. Warn CB, Rao LV, Maki SL, et al. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 1988; 60: 453.
32. Enjoji K, Miyata T, Kamikubo Y, et al. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, GLY 212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry 1995; 34: 5725.
33. Warshawsky I, Bu G, Mast A, et al. The carboxyl terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995; 95: 1773.
34. Wesselschmidt R, Likert K, Girard T, et al. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004.
35. Brisseau GF, Dackiw APB, Cheung PYC, et al. Posttranscriptional regulation of macrophage tissue factor expression by antioxidants. Blood 1995; 85: 1025.
36. Kirchhofer D, Kjell S, Sakariassen S, et al. Relationship between tissue factor expression and deposition of fibrin, platelets and leukocytes on cultured endothelial cells under venous blood flow conditions. Blood 1993; 81: 2050.
37. Tayler FB, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127.
38. Levi M, Cate HT, Bauer KA, et al. Inhibition of endotoxin-induced activation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114.
39. Day KC, Hoffman LC, Palmier MO, et al. Recombinant lipoprotein associated coagulation inhibitor inhibits tissue thrombo-plastin-induced intravascular coagulation in the rabbit. Blood 1993; 76: 1538.
40. Creasey AA, Chang ACK, Feigen L, et al. Tissue factor pathway inhibitor reduces mortality from Escherichia cou septic shock. J Clin Invest 1993; 91: 2850.
41. Sandset PM, Warn CB, Rao LV, et al. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88: 708.
42. Sandset PM, Warn CB, Maki SL, et al. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 1991; 78: 1496.
43. Warr TA, Rao LV, Rapaport SI, et al. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481.
44. Novotny WF, Brown SG, Miletich JP, et al. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387.
45. Bregengard C, Nordfang O, Wildgoose P, et al. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coagul Fibrinolysis 1993; 4: 699.
46. Palmier MO, Hall LJ, Reish CM, et al. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost 1993; 68: 33.